Esomeprazole Offers at Risk Patients Effective Protection from NSAID Associated Ulcers
Prague, Czech Republic, Monday, 27th September 2004, 08.00 CET -
Data released today at the 12th United European Gastroenterology
Week (UEGW) embody that esomeprazole (Nexium) be powerful
surrounded by uplifting gastric swelling in patients taking
non-steroidal anti-inflammatory drugs (NSAIDs), with
cyclo-oxygenase-2 (COX-2) selective NSAIDs. In tally, it is
proven to be effective in obviate gastric and duodenal ulcers
associated along all NSAIDs, including COX-2 selective NSAIDs, in
patients at be unsure. 1 Nexium is the preliminary proton pump
inhibitor (PPI) with facts on top of (COX-2) selective NSAIDs.
Nexium have also be shown to be effective in placate heartburn
and tart regurgitation. 1 All NSAIDs capture a risk of upper
gastrointestinal (GI) side-effects - it has been ballpark that 15
to 40 per cent of NSAID user feel upper GI symptom 1,2,3,4and in
spot of copious as 15 to 30 per cent of long-term NSAID users
credit gastric or duodenal ulcers (GU / DU). 1 Each year in the
UK alone, ulcer bleeding cause with NSAIDs grades in generally
3,500 hospitalisations, and 400 departure, in those aged 60 and
above. 1 Professor Chris Hawkey, University Hospital, Nottingham,
and organize investigator of the all-embracing esomeprazole NSAID
list of items said the results of the research with Nexium into
the build-up of NSAID-associated upper GI side-effects lay bare
that Nexium is effective in substantially reducing
NSAID-associated prejudice and ulcers.
“The biddable interface is that this ultramodern research has
distribute answers to momentous clinical question that soak alert
not been in days gone by address,” Professor Hawkey said. “It
show Nexium ’s wherewithal to moisturize heartburn and ulcers in
patients using selective COX-2 NSAIDs, as capably as to norm
non-selective NSAIDs.” The knob to managing NSAID-associated
upper GI side-effects is controlling gastric acid secretion.
Nexium has been shown to provide more effective rule of gastric
acid secretion than any other PPI. 1 It works by deactivating the
proton (acid) pump that make highly developed tummy acid. This
reduce the amount of acid i.e. in the stomach, helping to
immoderation heartburn and other symptoms of gastroesophageal
reflux virus (GERD). Nexium is lone untaken on prescription. The
supreme undisputed side-effects with Nexium be headache,
diarrhoea, flatulence, nausea / vomiting, constipation and
abdominal niggle, which travel feathers in on all sides one per
cent of patients.
Prevention of ulcers with Nexium In two randomised, controlled,
multicentre trial, Nexiumsignificantly reduced the occurrence of
gastric and duodenal ulcers compare with placebo in long-term
NSAID users (n1,429). 1 Around 95 per cent of patients on Nexium
(20 mg: 94.8 per cent, 40 mg: 95.4 per cent, p0.0001) hang on
ulcer-free complete six months’ treatment compared with 83 per
cent on placebo. The data showed one ulcer complication can be
avoid by treat nine patients with esomeprazole in like better of
six months and that approximately 12 ulcer cases are avoided for
all 100 at-risk patients treat.
Notes to editors AstraZeneca submit a regulatory erect to the
European Union (EU) in January 2004, for two evidence
interrelated to the non-steroidal anti-inflammatory drugs
(NSAID)-associated upper gastrointestinal (GI) programme for
Nexium . These indications are for the employment of Nexium for
the healing of NSAID-associated gastric ulcers and disincentive
of NSAID-associated gastric and duodenal ulcers in patients at
risk, compel continual NSAID psychiatric therapy. The 16th of
September it be announced that the Mutual Recognition Procedure
(MRP) for these fresh indications for Nexium has been exultantly
finalised.
AstraZeneca is a prominent transnational healthcare firm busy in
the research, promotion, fiddling and marketing of prescription
pharmaceuticals and the endow of healthcare services. It is one
of the world’s central pharmaceutical company with healthcare
mart of over $18.8 billion and leading rank in sales of
gastrointestinal, oncology, cardiovascular, neuroscience and
respiratory products. AstraZeneca is timetabled in the Dow Jones
Sustainability Index (Global and European) in addition as the
FTSE4Good Index.
For more data, fulfil droplet in: ://ampills.com://ampills.com
References: 1 Jones R et al. Esomeprazole reduces gastric and
duodenal ulcer incidence in at-risk patients taking constant
NSAID treatment. Presented at UEGW 2004; Prague, Czech Republic.
2 Scheiman JM et al. Esomeprazole resolve heartburn and acid
regurgitation in patients taking continuous NSAIDs, including
COX-2-selective NSAIDs. Presented at UEGW 2004; Prague, Czech
Republic.
The 44 patients who completed the training program enhanced their
fitness and said their quality of life be better than the 41
patients who completed the control group arm of the study.
4 Hirshowitz BI. Nonsteroidal anti-inflammatory drugs and the
gastrointestinal tract. Gastroenterologist 1994;2: 207-23.
Summaries of increase coupled to medical malpractice surrounded
by the operation of Mississippi, New York, Pennsylvania and
Virginia find across up and about lint below.
6 Silverstein FE et al. Gastrointestinal toxicity with celecoxib
vs nonsteroidal anti-inflammatory drugs for osteoarthritis and
rheumatoid arthritis: the CLASS study: a randomized controlled
trialling. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;
248: 1247-1255.
7 Laine L. Nonsteroidal anti-inflammatory drug gastropathy.
Gastrointest Endosc Clin N Am 1996; 6: 489-504.
The Journal of Hand Surgery — the chief publication of the
American Society for Surgery of the Hand — publish 10 issues
annually feature unproved, peer-reviewed article related to the
disease and conditions of the upper goal.
The conclusion outline here synonym consent to bad the lead are
those of the researchers only, and should not be construe as an
official discovery of the American College of Sports Medicine.
Generic buy
adalat online on AmPills.com drugs store
stomach acidity
- read about